Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $22.80 Consensus Price Target from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $22.80.

A number of brokerages recently issued reports on ZVRA. HC Wainwright set a $26.00 price objective on Zevra Therapeutics in a report on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Friday. Canaccord Genuity Group lowered their price target on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. Cantor Fitzgerald reduced their price objective on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Finally, Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th.

Zevra Therapeutics Stock Down 1.3%

ZVRA opened at $8.38 on Tuesday. Zevra Therapeutics has a 12 month low of $6.19 and a 12 month high of $13.16. The company has a market cap of $471.79 million, a PE ratio of 17.83 and a beta of 1.08. The company has a current ratio of 8.62, a quick ratio of 8.57 and a debt-to-equity ratio of 0.46. The company has a 50 day moving average of $8.73 and a 200 day moving average of $9.64.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.03. The firm had revenue of $26.06 million for the quarter, compared to the consensus estimate of $26.64 million. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%. On average, sell-side analysts expect that Zevra Therapeutics will post -1.95 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ZVRA. SG Americas Securities LLC purchased a new stake in shares of Zevra Therapeutics in the fourth quarter worth $121,000. JPMorgan Chase & Co. increased its stake in Zevra Therapeutics by 1,458.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 438,984 shares of the company’s stock worth $4,175,000 after acquiring an additional 410,823 shares during the last quarter. Cantor Fitzgerald L. P. raised its holdings in shares of Zevra Therapeutics by 487.9% in the 3rd quarter. Cantor Fitzgerald L. P. now owns 117,576 shares of the company’s stock valued at $1,118,000 after acquiring an additional 97,575 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of Zevra Therapeutics by 458.5% during the 3rd quarter. NewEdge Advisors LLC now owns 22,338 shares of the company’s stock valued at $212,000 after acquiring an additional 18,338 shares during the last quarter. Finally, Caxton Associates LLP bought a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at about $165,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.